Skip to content

Romiplostim N01

DRUG13 trials

Sponsors

Shandong University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Acute Myeloid LeukemiaAdolescentBreast CancerCTIT-Chemotherapy Induced ThrombocytopeniaCTIT: Cancer Therapy Induced ThrombocytopeniaCancer Treatment-induced Thrombocytopenia (CTIT)Chemotherapy Induced ThrombocytopeniaChemotherapy-induced Thrombocytopenia

Phase 1

Phase 2

Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT
RecruitingNCT06693791
Anhui Provincial HospitalPlatelet Recovery After Umbilical Cord Blood Transplantation
Start: 2024-12-01End: 2026-12-01Target: 34Updated: 2024-11-18
Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia
Not yet recruitingNCT06898983
Anhui Provincial HospitalCancer Treatment-induced Thrombocytopenia (CTIT)
Start: 2025-03-31End: 2027-02-28Target: 97Updated: 2025-03-28
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
Not yet recruitingNCT07043894
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdolescent, Chemotherapy Induced Thrombocytopenia, Children +2
Start: 2025-07-01End: 2026-09-01Target: 50Updated: 2025-06-29
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
RecruitingNCT07063225
Institute of Hematology & Blood Diseases Hospital, ChinaChemotherapy-induced Thrombocytopenia, Romiplostim N01
Start: 2025-08-31End: 2026-08-31Target: 50Updated: 2025-07-14
Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors
Not yet recruitingNCT07128576
Zhujiang HospitalSolid Tumors
Start: 2025-09-15End: 2028-12-31Target: 60Updated: 2025-09-04
Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy
Not yet recruitingNCT07400250
Peking Union Medical College HospitalPrimary Immune Thrombocytopenia (ITP)
Start: 2026-04-01End: 2028-10-01Target: 28Updated: 2026-02-10

Phase 3

Unknown Phase